BriaCell Total Stockholder Equity from 2010 to 2025

BCTXW Stock  USD 0.10  0  4.80%   
BriaCell Therapeutics Total Stockholder Equity yearly trend continues to be fairly stable with very little volatility. Total Stockholder Equity is likely to outpace its year average in 2025. Total Stockholder Equity is the total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders. View All Fundamentals
 
Total Stockholder Equity  
First Reported
2006-07-31
Previous Quarter
M
Current Value
3.6 M
Quarterly Volatility
13.2 M
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check BriaCell Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among BriaCell Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 18.4 K, Interest Expense of 0.0 or Other Operating Expenses of 40.2 M, as well as many indicators such as Price To Sales Ratio of 0.0, Days Sales Outstanding of 0.0 or Invested Capital of 622.1 K. BriaCell financial statements analysis is a perfect complement when working with BriaCell Therapeutics Valuation or Volatility modules.
  
Check out the analysis of BriaCell Therapeutics Correlation against competitors.

Latest BriaCell Therapeutics' Total Stockholder Equity Growth Pattern

Below is the plot of the Total Stockholder Equity of BriaCell Therapeutics Corp over the last few years. It is the total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders. BriaCell Therapeutics' Total Stockholder Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in BriaCell Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Total Stockholder Equity10 Years Trend
Very volatile
   Total Stockholder Equity   
       Timeline  

BriaCell Total Stockholder Equity Regression Statistics

Arithmetic Mean4,749,481
Geometric Mean2,195,910
Coefficient Of Variation310.49
Mean Deviation8,495,157
Median751,301
Standard Deviation14,746,633
Sample Variance217.5T
Range61M
R-Value(0.02)
Mean Square Error232.9T
R-Squared0.0004
Significance0.94
Slope(63,391)
Total Sum of Squares3261.9T

BriaCell Total Stockholder Equity History

2025-2.6 M
2024-2.7 M
2023-2.4 M
2022-3.8 M
202110.3 M
202057.3 M
2019-3.3 M

About BriaCell Therapeutics Financial Statements

BriaCell Therapeutics investors use historical fundamental indicators, such as BriaCell Therapeutics' Total Stockholder Equity, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in BriaCell Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Total Stockholder Equity-2.7 M-2.6 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for BriaCell Stock Analysis

When running BriaCell Therapeutics' price analysis, check to measure BriaCell Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BriaCell Therapeutics is operating at the current time. Most of BriaCell Therapeutics' value examination focuses on studying past and present price action to predict the probability of BriaCell Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BriaCell Therapeutics' price. Additionally, you may evaluate how the addition of BriaCell Therapeutics to your portfolios can decrease your overall portfolio volatility.